JP2021503276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503276A5 JP2021503276A5 JP2020520056A JP2020520056A JP2021503276A5 JP 2021503276 A5 JP2021503276 A5 JP 2021503276A5 JP 2020520056 A JP2020520056 A JP 2020520056A JP 2020520056 A JP2020520056 A JP 2020520056A JP 2021503276 A5 JP2021503276 A5 JP 2021503276A5
- Authority
- JP
- Japan
- Prior art keywords
- cell epitope
- regulatory
- cells
- isolated
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 14
- 210000003289 regulatory T cell Anatomy 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000002602 induced regulatory T cell Anatomy 0.000 claims 1
- 210000002501 natural regulatory T cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023075635A JP2023106434A (ja) | 2017-10-05 | 2023-05-01 | 制御性ｔ細胞エピトープ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568630P | 2017-10-05 | 2017-10-05 | |
| US201762568625P | 2017-10-05 | 2017-10-05 | |
| US62/568,630 | 2017-10-05 | ||
| US62/568,625 | 2017-10-05 | ||
| US201862729792P | 2018-09-11 | 2018-09-11 | |
| US62/729,792 | 2018-09-11 | ||
| PCT/US2018/054595 WO2019071116A1 (en) | 2017-10-05 | 2018-10-05 | T REGULATORY LYMPHOCYTE EPITOPES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075635A Division JP2023106434A (ja) | 2017-10-05 | 2023-05-01 | 制御性ｔ細胞エピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503276A JP2021503276A (ja) | 2021-02-12 |
| JP2021503276A5 true JP2021503276A5 (enExample) | 2021-11-18 |
| JP7274472B2 JP7274472B2 (ja) | 2023-05-16 |
Family
ID=65994377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520056A Active JP7274472B2 (ja) | 2017-10-05 | 2018-10-05 | 制御性ｔ細胞エピトープ |
| JP2023075635A Ceased JP2023106434A (ja) | 2017-10-05 | 2023-05-01 | 制御性ｔ細胞エピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075635A Ceased JP2023106434A (ja) | 2017-10-05 | 2023-05-01 | 制御性ｔ細胞エピトープ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11441122B2 (enExample) |
| EP (1) | EP3691673A4 (enExample) |
| JP (2) | JP7274472B2 (enExample) |
| AU (1) | AU2018346681B2 (enExample) |
| CA (1) | CA3077084A1 (enExample) |
| WO (1) | WO2019071116A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023520989A (ja) * | 2020-03-27 | 2023-05-23 | エピバックス・インコーポレーテッド | １型糖尿病の予防および治療に有用なｔレジトープ構築物 |
| CA3172976A1 (en) * | 2020-03-27 | 2021-09-30 | Epivax, Inc. | Regulatory t cell epitopes |
| JP2023543801A (ja) * | 2020-09-25 | 2023-10-18 | エピバックス、インコーポレイテッド | レトロインベルソ制御性ｔ細胞エピトープ |
| GB202100194D0 (en) * | 2021-01-07 | 2021-02-24 | Cambridge Entpr Ltd | Inhibition of T-Cell activity |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| CA2216239A1 (en) | 1995-03-24 | 1996-10-03 | The Scripps Research Institute | Methods for identifying a factor v gene mutation |
| WO2002060917A2 (en) * | 2000-12-01 | 2002-08-08 | Regents Of The University Of Minnesota | Method to treat hemophilia |
| WO2003087161A1 (en) * | 2002-04-18 | 2003-10-23 | Merck Patent Gmbh | Modified factor viii |
| KR20050062572A (ko) * | 2002-10-01 | 2005-06-23 | 가부시키가이샤 디나벡크 겐큐쇼 | ＴＡＰ 활성의 저해에 의해 ＭＨＣ ｃｌａｓｓ Ⅰ에 의한외래 에피토프의 제시를 증강시키는 방법 |
| EP1598367A1 (en) | 2004-05-18 | 2005-11-23 | ZLB Behring GmbH | Modified coagulation factors with enhanced stability and their derivatives |
| AU2007220825B2 (en) | 2006-02-23 | 2013-02-21 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis using variant forms of activated Factor V |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| KR101722305B1 (ko) | 2007-01-30 | 2017-03-31 | 에피백스, 인크. | 조절 ｔ 세포 에피토프, 그의 조성물 및 용도 |
| MX373641B (es) | 2011-04-29 | 2020-05-04 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para la terapia contra alergias. |
| US20160038575A1 (en) * | 2013-03-15 | 2016-02-11 | Haplomics, Inc. | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a |
| WO2016005564A2 (en) | 2014-07-11 | 2016-01-14 | Novo Nordisk A/S | Antibodies against activated factor v |
| US20180179256A1 (en) * | 2015-05-04 | 2018-06-28 | Epivax, Inc. | Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence |
| WO2019210187A1 (en) | 2018-04-26 | 2019-10-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
-
2018
- 2018-10-05 CA CA3077084A patent/CA3077084A1/en active Pending
- 2018-10-05 US US16/753,522 patent/US11441122B2/en active Active
- 2018-10-05 AU AU2018346681A patent/AU2018346681B2/en not_active Ceased
- 2018-10-05 JP JP2020520056A patent/JP7274472B2/ja active Active
- 2018-10-05 WO PCT/US2018/054595 patent/WO2019071116A1/en not_active Ceased
- 2018-10-05 EP EP18864161.7A patent/EP3691673A4/en active Pending
-
2022
- 2022-08-23 US US17/893,579 patent/US12275956B2/en active Active
-
2023
- 2023-05-01 JP JP2023075635A patent/JP2023106434A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014240404A5 (enExample) | ||
| JP2017165733A5 (enExample) | ||
| Klenerman | The (gradual) rise of memory inflation | |
| JP2021503276A5 (enExample) | ||
| Xu et al. | In vivo assembly of nanoparticles achieved through synergy of structure‐based protein engineering and synthetic DNA generates enhanced adaptive immunity | |
| JP2015131795A5 (enExample) | ||
| JP2010516290A5 (enExample) | ||
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2022130413A (ja) | Ｃｄ８＋ｔ細胞の誘導のための組成物および方法 | |
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| JP2019524140A5 (enExample) | ||
| McMahon et al. | The evolving role of mTOR inhibition in transplantation tolerance | |
| JP2018023397A5 (enExample) | ||
| JP2018528237A5 (enExample) | ||
| Brighenti et al. | Regulation of immunity to tuberculosis | |
| JP2016511221A5 (enExample) | ||
| MX2020003129A (es) | Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva. | |
| Faliti et al. | Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis | |
| JP2017520862A5 (enExample) | ||
| JP2017526742A5 (enExample) | ||
| CN114929863A (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| JP2013523084A5 (enExample) | ||
| Oldstone | The role of cytotoxic T lymphocytes in infectious disease: history, criteria, and state of the art | |
| Grover et al. | Heat killed Saccharomyces cerevisiae as an adjuvant for the induction of vaccine-mediated immunity against infection with Mycobacterium tuberculosis | |
| Kanno et al. | A bivalent recombinant mycobacterium bovis BCG expressing the S1 subunit of the pertussis toxin induces a polyfunctional CD4+ T cell immune response |